NASDAQ:GRTS
Gritstone Oncology Inc. Stock News
$0.787
+0.0408 (+5.46%)
At Close: May 17, 2024
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio to Participate in Upcoming Investor Conferences
05:30pm, Wednesday, 18'th Jan 2023
EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th
Gritstone bio: Keep An Eye On This Discounted Cancer Vaccine Developer In 2023
04:16am, Monday, 02'nd Jan 2023
Gritstone stock has tanked since the company's IPO but 2023 could be the year this biotech delivers. A personalised cancer vaccine specialist at heart, Gritstone's pivot into developing a COVID vaccin
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
04:31pm, Thursday, 15'th Dec 2022
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th
Why G Medical Innovations Shares Are Trading Lower By 35%; Here Are 25 Stocks Moving Premarket
12:45pm, Monday, 21'st Nov 2022 Benzinga
Gainers
EUDA Health Holdings Limited (NASDAQ: EUDA) shares rose 88.1% to $8.40 in pre-market trading after merger completed with 8i Acquisition SPAC last week.
Meta Materials Inc. (NASDAQ: MMAT) sha
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:30pm, Monday, 21'st Nov 2022 GlobeNewswire Inc.
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announ
Gritstone to Participate in Upcoming Investor Conferences
12:00pm, Thursday, 17'th Nov 2022 GlobeNewswire Inc.
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announ
Gritstone to Participate in Upcoming Investor Conferences
07:00am, Thursday, 17'th Nov 2022
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced
Block To 100? Plus This Analyst Slashes PT On Estée Lauder By 32%
11:58am, Monday, 07'th Nov 2022 Benzinga
Barclays slashed the price target on Block, Inc. (NYSE: SQ) from $130 to $100. Block shares rose 1% to $60.70 in pre-market trading.
Berenberg lowered The Estée Lauder Companies Inc. (NYSE: EL)
Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates
08:20pm, Thursday, 03'rd Nov 2022
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
07:31am, Tuesday, 01'st Nov 2022 Benzinga
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
02:13pm, Monday, 31'st Oct 2022 Benzinga
Upgrades
Morgan Stanley upgraded the previous rating for Pure Storage Inc (NYSE:PSTG) from Equal-Weight to Overweight. In the second quarter, Pure Storage showed an EPS of $0.32, compared to $0.14 fr
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Should You Buy?
02:01pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Gritstone bio Inc. (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Announces Private Placement of $45.0 Million
11:01am, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announ